Premium
Antibodies to hepatitis C virus in uremic patients on continuous ambulatory peritoneal dialysis
Author(s) -
Ng YeeYung,
Lee ShouDong,
Wu ShiaoChi,
Yang WuChang,
Chiang ShoouShan,
Huang TungPo
Publication year - 1991
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.1890350411
Subject(s) - continuous ambulatory peritoneal dialysis , medicine , hepatitis c virus , hemodialysis , ambulatory , peritoneal dialysis , antibody , dialysis , gastroenterology , incidence (geometry) , hepatitis c , immunoassay , virus , immunology , physics , optics
The prevalence of antibody to hepatitis C virus (anti‐HCV) among 101 uremic patients receiving continuous ambulatory peritoneal dialysis (CAPD) was evaluated using a synthetic peptidebased HCV antibodies enzyme immunoassay. Thirty (29.7%) were found anti‐HCV positive. This is significantly higher than 500 unselected paid blood donors (4.2%, P < 0.0001). Among CAPD patients, anti‐HCV positivity was found more frequently in patients who had received frequent and longer duration of hemodialysis previously (40.4% vs. 20.4%, P < 0.05). These findings suggest that hemodialysis patients have a higher risk of HCV infection. At present, CAPD may be a suitable way to reduce the incidence of HCV infection in uremic patients.